Zhejiang Batai Medical Technology raises $200M Series D for vascular intervention devices

What's the deal? Zhejiang Batai Medical Technology, a Chinese medtech company specialising in cardiovascular and peripheral vascular intervention devices, has closed a $200M Series D round. Shenzhen CDF CapitalDealroom has a profile for this one. Try Dealroom → led the investment, with participation from Zhejiang's "4+1" biomedical and high-end device industry fund, Junxingjian Capital, Zhongyiren CapitalDealroom has a profile for this one. Try Dealroom →, and Yifeng CapitalDealroom has a profile for this one. Try Dealroom →.

Batai Medical is a nationally recognised high-tech enterprise that develops, manufactures, and sells implantable medical devices. Its product portfolio includes paclitaxel-eluting balloon catheters for both coronary and peripheral arteries, vascular stent systems, angiographic catheters, guide catheters, and catheter sheath kits.

Why now? China's push for domestic substitution in high-end medical devices has accelerated in recent years, with government policy favouring locally made products in hospital procurement. Vascular intervention is one of the fastest-growing segments in China's medtech market, driven by an ageing population and rising rates of cardiovascular disease.

The participation of a provincial biomedical industry fund signals strong government backing for the sector.

What could go wrong? China's medtech market is increasingly crowded, with dozens of domestic players competing on price in the vascular intervention space. Volume-based procurement policies, while boosting adoption, have also compressed margins across the industry.

Regulatory hurdles for new devices remain significant, and international expansion — often necessary to justify large valuations — requires clearing additional approval processes in the US, EU, and other markets.

The signal: Batai Medical is classified as a "breakout stage" company on Dealroom, and the mix of backers here — corporate investor CDF Capital alongside multiple investment funds and a provincial industry fund — illustrates how Chinese medtech rounds increasingly blend state-backed and private capital to fast-track domestic champions. A D round of this size for a vascular device maker suggests the company is positioning for commercialisation at scale rather than early R&D bets.